MAPK8 and idiopathic pulmonary fibrosis: These cumulative data on CC-930 pharmacology, coupled with an appreciation for the dependency of fibrosis on the JNK pathway, as well as the remaining unmet medical needs in IPF medical treatment, led us to evaluate CC-930 in a series of nonclinical and clinical studies aimed at developing a novel therapy for IPF.